Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Completed
Plexxikon
Phase 1
2012-05-01
This was a 3-part study designed to explore the safety and tolerability of escalating doses
of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm
RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy
of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in
participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory
epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
